There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Iovance Biotherapeutics (IOVA) and Xeris Pharmaceuticals (XERS) with bullish sentiments.
Iovance Biotherapeutics (IOVA)
In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Iovance Biotherapeutics, with a price target of $33.00. The company’s shares closed last Monday at $23.69, close to its 52-week high of $26.59.
According to TipRanks.com, Livshits is a 4-star analyst with an average return of 11.1% and a 52.4% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Crispr Therapeutics AG, and Intellia Therapeutics.
Iovance Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $31.00, representing a 31.5% upside. In a report issued on November 11, H.C. Wainwright also reiterated a Buy rating on the stock with a $32.00 price target.
See today’s analyst top recommended stocks >>
Xeris Pharmaceuticals (XERS)
In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on Xeris Pharmaceuticals, with a price target of $22.00. The company’s shares closed last Monday at $7.81, close to its 52-week low of $6.85.
According to TipRanks.com, Yang is ranked 0 out of 5 stars with an average return of -6.5% and a 34.3% success rate. Yang covers the Healthcare sector, focusing on stocks such as Audentes Therapeutics, Revance Therapeutics, and Nektar Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Xeris Pharmaceuticals with a $20.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
